Blinded sample size re-estimation in crossover bioequivalence trials

Pharmaceutical Statistics

Volumn 13, Issue 3, 2014, Pages 157-162

  Golkowski, Daniel ^a   Friede, Tim ^b   Kieser, Meinhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

bioequivalence; crossover trials; internal pilot study; sample size re estimation

Indexed keywords

ALGORITHM; ANALYSIS OF VARIANCE; ARTICLE; BIOEQUIVALENCE; CALCULATION; CROSSOVER PROCEDURE; HYPOTHESIS; SAMPLE SIZE; STATISTICAL MODEL; CLINICAL TRIAL (TOPIC); DRUG DESIGN; HUMAN; METHODOLOGY; PHARMACOKINETICS; PILOT STUDY; PROCEDURES; THERAPEUTIC EQUIVALENCE;

CLINICAL TRIALS AS TOPIC; CROSS-OVER STUDIES; DRUG DESIGN; HUMANS; PHARMACOKINETICS; PILOT PROJECTS; RESEARCH DESIGN; SAMPLE SIZE; THERAPEUTIC EQUIVALENCY;

EID: 84901234013     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1617     Document Type: Article

References (25)

1. Food and Drug Administration. Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products General Considerations, 2000. (Available from: http://www.fda.gov/downloads/Drugs/./ Guidances/ucm201790.pdf) [accessed 17 March 2014].
2. Hauschke D, Steinijans V, Pigeot I,. Bioequivalence Studies in Drug Development: Methods and Applications. Wiley: Chichester, England, 2007.
3. Patterson S, Jones B,. Bioequivalence and Statistics in Clinical Pharmacology. Chapman & Hall/CRC: New York, 2006.
4. Banyopadhya N, Dragalin V,. Implementation of an adaptive group sequential design in a bioequivalence study. Pharmaceutical Statistics 2007; 6: 115-122.
5. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J,. PhRMA Working Group. Adaptive designs in clinical drug development-an executive summary of the PhRMA working group. Journal of Biopharmaceutical Statistics 2006; 16: 275-283, Discussion 285-291, 293-298, 311-312.
6. Phillips AJ, Keene ON,. Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group. Pharmaceutical Statistics 2006; 5: 61-66.
7. Montague TH,. Adaptive designs for bioequivalence trials. PhD thesis. University of Reading, School of Biological Science, 2007.
8. Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ, Smith RA,. Sequential design approaches for bioequivalence studies with crossover designs. Pharmaceutical Statistics 2008; 7: 245-262.
9. Montague TH, Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ,. Additional results for 'sequential design approaches for bioequivalence studies with crossover designs. Pharmaceutical Statistics 2012; 11: 8-13.
10. The European Agency for Evaluation of Medicinal Products (EMEA). Committee for medicinal products for human use (CHMP). Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design, 2007. (Available from: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003616.pdf) [Accessed 17 March 2014].
11. Jones B, Kenward MG,. Design and Analysis of Cross-over Trials (2nd edn), Vol. 98. Chapman Hall/CRC: Boca Raton, Fla, 2003.
12. Hauschke D, Kieser M, Diletti E, Burke M,. Sample size determination for proving equivalence based on the ratio of two means for normally distributed data. Statistics in Medicine 1999; 18: 93-105.
13. Kieser M, Friede T,. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Statistics in Medicine 2000; 19: 901-911.
14. Kieser M, Friede T,. Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Statistics in Medicine 2003; 22: 3571-3581.
15. Friede T, Kieser M,. Blinded sample size reassessment in noninferiority and equivalence trials. Statistics in Medicine 2003; 22: 995-1007.
16. Golkowski D,. Blinded sample size re-estimation in cross-over bioequivalence trials. Diplomarbeit (MSc dissertation), University of Heidelberg, 2012.
17. Miller F,. Variance estimation in clinical studies with interim sample size reestimation. Biometrics 2005; 61: 355-361.
18. Berger RL, Boos DD,. P values maximized over a confidence set for the nuisance parameter. Journal of the American Statistical Association 1994; 89: 1012-1016.
19. Friede T, Kieser M,. Sample size reassessment in non-inferiority trials. internal pilot study designs with ANCOVA. Methods of Information in Medicine 2011; 50: 237-243.
20. Zucker DM, Wittes JT, Schabenberger O, Brittain E,. Internal pilot studies II: comparison of various procedures. Statistics in Medicine 1999; 18: 3493-3509.
21. Steinijans VW, Sauter R, Hauschke D, Diletti E, Schall R, Luus HG, Elze M, Blume H, Hoffmann C, Franke G, Siegmund W,. Reference tables for the intrasubject coefficient of variation in bioequivalence studies. International Journal of Clinical Pharmacology and Therapeutics 1995; 33: 427-430.
22. European Medicines Agency (EMEA). Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr), 2010. (Available from: http://www.ema.europa.eu/pdfs/human/qwp/140198enrev1fin.pdf) [Accessed: 05.07.2013].
23. Glimm E, Läuter J,. Some notes on blinded sample size re-estimation. arXiv: 1301.4167v1 [stat.ME].
24. Whitehead J, Whitehead A, Todd S, Bolland K, Sooriyarachchi MR,. Mid-trial design reviews for sequential clinical trials. Statistics in Medicine 2001; 20: 165-176.
25. Friede T, Miller F,. Blinded continuous monitoring of nuisance parameters in clinical trials. Journal of the Royal Statistical Society Series C 2012; 61: 601-618.